Statistical analysis The primary population for efficacy analyses consisted of all randomized participants who completed treatment and had evaluable DEXA lean body mass data at baseline and at the scheduled week 24 visit (designated as the completer population in the Statistical Analysis Plan)
and change from baseline to week 104 in waist circumference and systolic blood pressure
Some insurance plans may require prior authorization or step therapy, meaning patients might need to try other treatments before being eligible for Semaglutide
I tried bupropion, topomax, phentermine, no result
The pivotal trial showed an average weight loss of approximately 12.4%, or about 27 pounds, at the highest tested dose over 72 weeks, with meaningful reductions in blood pressure and other cardiovascular markers, according to data cited by Physicians Weekly
FDAs Concerns with Unapproved GLP-1 Drugs Used for Weight Loss | FDA RetatrutideA Game Changer in Obesity Pharmacotherapy PMC Tirzepatide (subcutaneous route) Side effects & dosage Mayo Clinic GLP-1 Receptor Agonist Market Size | Industry Report, 2033